Latest News and Press Releases

EBC Financial Group announces regulatory approval of its South African subsidiary, positioning the firm for future access to the country’s financial sector

Agios today announced that the CHMP has adopted a positive opinion for the new indication for PYRUKYND in adults for anemia associated with thalassemia

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safetyPhase 2 clinical trial initiation anticipated before the end of 2025Trial builds on positive Phase 1...

MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative treatment for patients on peritoneal...

Agios announced that the U.S. FDA has extended the PDUFA goal date for the sNDA of PYRUKYND for adults with thalassemia by three months to December 7, 2025

A newly established global alliance integrating specialized expertise in oncology, medical imaging, patient recruitment as well as pharmacokinetics and pharmacodynamics studiesComprehensive access to...

Palo Alto, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the Paradise™ Ultrasound Renal...

Palo Alto, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the Paradise™ Ultrasound Renal...

LAKELAND, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Metrc, a leading provider of regulatory track-and-trace systems for highly regulated industries, announced a strategic partnership with BioTrack, a...

Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia